NMPA (China) approves Symplicity Spyral renal denervation (RDN) system – Medtronic

Medtronic announced it received approval from the National Medical Products Administration (NMPA) in China for its Symplicity Spyral renal denervation (RDN) system, also known as the Symplicity blood pressure procedure.

Symplicity Spyral is the first RDN system in China to receive NMPA approval. The company intends to go through the provincial registration process and expects sales of Symplicity Spyral in China to be modest in the short-term.

Hypertension is one of the most prominent public health challenges in China, with over 245 million people affected by the condition. Further, only 13.8% of those living with hypertension in China have their condition under control. Worldwide, control rates remain low, despite available medications and lifestyle interventions. These challenges speak to the possibility that patients may benefit from an adjunctive treatment option to better manage their blood pressure.